Tamsulosin Hydrochloride
Product Images NDC 58118-0598

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 58118-0598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tamsulosin 0.4mg

This is an advertisement for Tamsulosin 0.4mg capsules sold at a wholesale price by Clinical Solutions. It includes details such as the National Drug Code (NDC) and quantity being sold (30 capsules), and the manufacturer's NDC and lot/batch number. The manufacturer is identified as "Aucbiio Phrma Lined" and the product is set to expire in 2021. There is also a mention of a location in California, USA.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

This appears to be a figure or graph depicting the mean plasma concentrations of Tamsulosin Hydrochloride capsules 0.4 mg under fasted and fed conditions. There is a time axis in hours and two lines indicating the concentrations under each condition. No further interpretation can be made without the graph itself.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

The image shows the mean change from baseline in total AUA symptom score (ranging from 0 to 35) in Study 2 for the treatments of 0.08mg LNT, 0.4mg LNT, and placebo. The duration of treatment in weeks is indicated on the bottom axis. The data is displayed in a bar graph format.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

The figure shows the mean increase in peak urine flow rate in L/sec for Study 1. The treatment group received either 0.08mg or 0.4mg, while the control group received a placebo. The duration of treatment was measured in weeks, and the study had a total sample size of 635, 621, 617, 754, 755, 752, 713, and 694, respectively.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

This text is describing a figure labeled Figure 3B which shows the mean increase in peak urine flow rate in mL/Sec for Study 2. The figure has a chart with different treatment options along the horizontal axis and the mean increase in peak urine flow rate on the vertical axis. The chart shows that the treatment option with the highest mean increase in peak urine flow rate is located around 20. The text also includes a legend for the chart which includes a symbol and abbreviation key. The duration of the treatment is also shown on the horizontal axis in weeks.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.